Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.
Risk & Volatility
Lexicon Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Profitability
This table compares Lexicon Pharmaceuticals and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexicon Pharmaceuticals | -14,573.20% | -138.54% | -71.29% |
| Cyclacel Pharmaceuticals | N/A | -448.19% | -151.29% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexicon Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
| Cyclacel Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
Lexicon Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 201.20%. Cyclacel Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 999.48%. Given Cyclacel Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.
Insider & Institutional Ownership
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Lexicon Pharmaceuticals and Cyclacel Pharmaceuticals’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexicon Pharmaceuticals | $1.20 million | 338.58 | -$177.12 million | ($0.80) | -2.06 |
| Cyclacel Pharmaceuticals | $420,000.00 | 6.47 | -$22.56 million | ($27.22) | -0.08 |
Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Lexicon Pharmaceuticals beats Cyclacel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
